| BETTA-PHARMACEUTICALS |
BETTA-PHARMACEUTICALS |
90%
|
License and collaboration agreement with Betta Pharmaceuticals for development and commercialization in Greater China |
| ROCHE |
ROCHE |
85%
|
the Company and Roche agreed to collaborate in the research, development, manufacture and commercialization of target-binding degrader medicines |
| AZN |
AstraZeneca PLC |
72%
|
ies and no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources, and ti… |
| AZN |
AstraZeneca PLC |
72%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from CCCC graph: ies and no experience in marketing products. We intend to develop an in-house marketing organization and sales force, … |
| GLUE |
Monte Rosa Therapeutics, Inc. |
72%
|
ies and no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources, and ti… |
| GLUE |
Monte Rosa Therapeutics, Inc. |
72%
|
Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t… |
| KYMR |
Kymera Therapeutics, Inc. |
72%
|
ies and no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources, and ti… |
| KYMR |
Kymera Therapeutics, Inc. |
72%
|
Reciprocal relationship from KYMR graph: hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to u… |
| NRIX |
Nurix Therapeutics, Inc. |
72%
|
ies and no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources, and ti… |
| NRIX |
Nurix Therapeutics, Inc. |
72%
|
Reciprocal relationship from NRIX graph: Reciprocal relationship from CCCC graph: ies and no experience in marketing products. We intend to develop an in-house marketing organization and sales force,… |
| BIIB |
Biogen Inc. |
62%
|
Reciprocal relationship from BIIB graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from BIIB graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from BIIB g… |
| BIOGEN-MA-INC |
BIOGEN-MA-INC |
62%
|
tion rights under certain circumstances, including but not limited to insolvency or a material breach by the other party, subject to certain conditions. Roche Agreement accounting At commencement, th… |
| C4T-SECURITIES-CORPORATION |
C4T-SECURITIES-CORPORATION |
62%
|
cialization, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, lack of marketing and sales history, product liability, prote… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
andards and requirements, and insider trading laws. We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs, CMOs, and consultants may engage in… |
| DOHME-LLC |
DOHME-LLC |
62%
|
en fully allocated. Merck License and Collaboration Agreement On December 11, 2023, the Company and Merck Sharp & Dohme, LLC, or Merck, entered into an exclusive license and collaboration agreement, … |
| EVERCORE-GROUP |
EVERCORE-GROUP |
62%
|
latory review of our product candidates; • the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any … |
| EVR |
Evercore Inc. |
62%
|
Reciprocal relationship from EVR graph: Reciprocal relationship from CCCC graph: latory review of our product candidates; • the costs and timing of preparing, filing and prosecuting patent applicatio… |
| MRK |
Merck & Co., Inc. |
62%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from CCCC graph: en fully allocated. Merck License and Collaboration Agreement On December 11, 2023, the Company and Merck Sharp & Dohm… |
| USA-LLC |
USA-LLC |
62%
|
andards and requirements, and insider trading laws. We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs, CMOs, and consultants may engage in… |
